Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 25 July, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo
Stock Ticker - BSE: 541299 | NSE: DLCL

Fundamental Analysis of Dr Lalchandani Labs Ltd

Share Price and Basic Stock Data

Last Updated: July 25, 2024, 10:02 pm

Market Cap 11.4 Cr.
Current Price 26.2
High / Low35.0/15.7
Stock P/E18.3
Book Value 22.0
Dividend Yield0.00 %
ROCE6.53 %
ROE6.95 %
Face Value 10.0
PEG Ratio3.17

Data Source: screener.in

Competitors of Dr Lalchandani Labs Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Dr Lalchandani Labs Ltd 11.4 Cr. 26.235.0/15.718.3 22.00.00 %6.53 %6.95 % 10.0
Dolphin Medical Services Ltd 2.79 Cr. 1.853.25/1.41 6.670.00 %0.83 %0.99 % 10.0
Dhanvantri Jeevan Rekha Ltd 7.84 Cr. 19.127.7/10.346.1 23.10.00 %2.77 %1.81 % 10.0
Deccan Health Care Ltd 73.9 Cr. 36.242.0/20.548.6 47.60.00 %2.55 %1.70 % 10.0
Chennai Meenakshi Multispeciality Hospital Ltd 27.1 Cr. 36.354.6/21.0 0.440.00 %9.34 %% 10.0
Industry Average24,837.45 Cr990.8766.62106.050.39%12.05%11.51%8.63

Quarterly Result

MonthMar 2019Sep 2019Mar 2020Sep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024
Sales2.643.033.072.717.078.023.262.282.762.732.08
Expenses1.952.302.532.145.406.072.812.462.502.381.04
Operating Profit0.690.730.540.571.671.950.45-0.180.260.351.04
OPM %26.14%24.09%17.59%21.03%23.62%24.31%13.80%-7.89%9.42%12.82%50.00%
Other Income0.010.000.000.000.000.000.000.010.000.000.24
Interest0.050.090.090.050.300.240.330.480.510.110.28
Depreciation0.200.210.220.230.290.280.300.330.340.330.29
Profit before tax0.450.430.230.291.081.43-0.18-0.98-0.59-0.090.71
Tax %26.67%0.00%82.61%24.14%27.78%25.17%22.22%0.00%0.00%0.00%0.00%
Net Profit0.340.430.040.230.791.07-0.13-0.97-0.59-0.090.71
EPS in Rs0.780.990.090.531.822.47-0.30-2.24-1.36-0.211.64

Last Updated: July 14, 2024, 7:45 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: July 25, 2024, 6:08 pm

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Sales2.795.266.109.7811.285.044.81
Expenses2.174.064.847.548.814.953.43
Operating Profit0.621.201.262.242.470.091.38
OPM %22.22%22.81%20.66%22.90%21.90%1.79%28.69%
Other Income0.030.010.000.000.000.000.24
Interest0.160.140.180.350.600.990.38
Depreciation0.130.350.420.520.590.660.62
Profit before tax0.360.720.661.371.28-1.560.62
Tax %25.00%26.39%28.79%26.28%28.12%0.00%0.00%
Net Profit0.260.530.471.010.93-1.560.62
EPS in Rs0.891.221.082.332.15-3.601.43
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)103.85%-11.32%114.89%-7.92%-267.74%139.74%
Change in YoY Net Profit Growth (%)0.00%-115.17%126.21%-122.81%-259.82%407.49%

Growth

Compounded Sales Growth
10 Years:%
5 Years:-2%
3 Years:-21%
TTM:-5%
Compounded Profit Growth
10 Years:%
5 Years:3%
3 Years:-15%
TTM:140%
Stock Price CAGR
10 Years:%
5 Years:10%
3 Years:1%
1 Year:-4%
Return on Equity
10 Years:%
5 Years:3%
3 Years:0%
Last Year:7%

Last Updated: July 9, 2024, 5:56 pm

Balance Sheet

Last Updated: July 10, 2024, 12:25 pm

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Equity Capital2.934.334.334.334.334.334.33
Reserves0.403.734.215.226.154.595.21
Borrowings1.880.901.764.045.156.403.48
Other Liabilities1.001.181.631.612.492.401.97
Total Liabilities6.2110.1411.9315.2018.1217.7214.99
Fixed Assets2.063.283.475.245.755.393.99
CWIP0.000.000.000.000.000.000.00
Investments0.240.240.240.240.240.240.41
Other Assets3.916.628.229.7212.1312.0910.59
Total Assets6.2110.1411.9315.2018.1217.7214.99

Reserves and Borrowings Chart

Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity 0.58-0.45-0.101.192.010.00-0.22
Cash from Investing Activity -1.29-1.95-0.53-2.26-1.53-0.201.00
Cash from Financing Activity 1.573.510.851.710.16-0.23-1.59
Net Cash Flow0.851.120.230.640.64-0.43-0.81

Free Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-1.260.30-0.50-1.80-2.68-6.31-2.10

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days149.14126.99199.25148.54136.55359.93
Inventory Days167.03233.36158.7068.75191.07458.51
Days Payable426.86406.89355.4897.06175.15404.21
Cash Conversion Cycle-110.69-46.542.47120.23152.47414.23
Working Capital Days168.76170.70209.43132.86123.93287.51
ROCE %12.14%8.72%14.40%12.87%-3.68%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2018Mar 2019Sep 2019Mar 2020Sep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024
Promoters60.78%60.78%60.78%60.78%60.78%60.78%60.78%60.78%60.78%60.78%60.78%60.78%
Public39.22%39.22%39.22%39.22%39.22%39.22%39.22%39.22%39.23%39.22%39.21%39.22%
No. of Shareholders168151144143143143151157162164159165

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)1.43-3.612.152.331.09
Diluted EPS (Rs.)1.43-3.612.152.331.09
Cash EPS (Rs.)2.87-2.083.513.522.07
Book Value[Excl.RevalReserv]/Share (Rs.)22.0220.5624.1622.0119.68
Book Value[Incl.RevalReserv]/Share (Rs.)22.0220.5924.2022.0419.71
Revenue From Operations / Share (Rs.)11.1011.6326.0322.5714.09
PBDIT / Share (Rs.)1.000.205.555.122.93
PBIT / Share (Rs.)-0.43-1.334.203.931.95
PBT / Share (Rs.)1.43-3.612.973.181.52
Net Profit / Share (Rs.)1.43-3.612.152.331.09
PBDIT Margin (%)9.041.7521.3322.6820.78
PBIT Margin (%)-3.93-11.4016.1217.4113.85
PBT Margin (%)12.83-31.0011.4114.0810.82
Net Profit Margin (%)12.83-31.008.2710.347.76
Return on Networth / Equity (%)6.47-17.548.9110.605.56
Return on Capital Employeed (%)-1.89-4.6313.7113.818.39
Return On Assets (%)4.11-8.825.146.653.97
Long Term Debt / Equity (X)0.020.370.250.270.17
Total Debt / Equity (X)0.360.520.380.350.17
Asset Turnover Ratio (%)0.290.280.670.720.55
Current Ratio (X)1.882.072.222.984.07
Quick Ratio (X)1.601.781.902.753.80
Inventory Turnover Ratio (X)1.390.000.000.000.00
Interest Coverage Ratio (X)1.130.084.526.816.86
Interest Coverage Ratio (Post Tax) (X)-0.49-0.582.754.103.56
Enterprise Value (Cr.)7.9913.8914.816.532.77
EV / Net Operating Revenue (X)1.662.761.310.660.45
EV / EBITDA (X)18.37157.326.152.942.18
MarketCap / Net Operating Revenue (X)1.422.441.270.610.57
Price / BV (X)0.711.381.370.630.41
Price / Net Operating Revenue (X)1.422.441.270.610.57
EarningsYield0.09-0.120.060.160.13

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value: 28.54

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Undervalued: 8.93% compared to the current price 26.2

Intrinsic Value: 30.19

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Undervalued: 15.22% compared to the current price 26.2

Last 5 Year EPS CAGR: 5.77%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock is trading at a low valuation with an average P/B ratio of 1.66 and average Dividend Yield of 3.63%.
  2. The company has higher reserves (4.22 cr) compared to borrowings (3.37 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (6.44 cr) and profit (0.49 cr) over the years.
  1. The stock has a low average ROCE of 6.35%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 156.17, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 76.02, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dr Lalchandani Labs Ltd:
    1. Net Profit Margin: 12.83%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: -1.89% (Industry Average ROCE: 12.05%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ✓ ROE%: 6.47% (Industry Average ROE: 11.51%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): -0.49
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.60
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. ✓ Stock P/E: 18.3 (Industry average Stock P/E: 66.62)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. ✓ Total Debt / Equity: 0.36
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Dr. Lalchandani Labs Ltd. is a Public Limited Listed company incorporated on 02/08/2017 and has its registered office in the State of Delhi, India. Company’s Corporate Identification Number(CIN) is L85320DL2017PLC321605 and registration number is 321605. Currently Company is involved in the business activities of Activities of independent diagnostic/pathological laboratories. Company’s Total Operating Revenue is Rs. 11.28 Cr. and Equity Capital is Rs. 4.33 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Hospitals & Medical ServicesM-20, Basement, Greater Kailash, New Delhi Delhi 110048info@lalchandanipathlab.com
http://www.lalchandanipathlab.com
Management
NamePosition Held
Dr. Arjan Lal ChandaniChairman & Managing Director
Mr. Mohit Lal ChandaniWholeTime Director & CEO
Mrs. Anchal GuptaExecutive Director & CFO
Mr. Rajiv HandaIndependent Director
Mr. Prakash JhuraneyIndependent Director
Mrs. Swati ChandraNon Executive Director

FAQ

What is the latest fair value of Dr Lalchandani Labs Ltd?

The latest fair value of Dr Lalchandani Labs Ltd is ₹28.54.

What is the Market Cap of Dr Lalchandani Labs Ltd?

The Market Cap of Dr Lalchandani Labs Ltd is 11.4 Cr..

What is the current Stock Price of Dr Lalchandani Labs Ltd as on 25 July 2024?

The current stock price of Dr Lalchandani Labs Ltd as on 25 July 2024 is 26.2.

What is the High / Low of Dr Lalchandani Labs Ltd stocks in FY 2024?

In FY 2024, the High / Low of Dr Lalchandani Labs Ltd stocks is 35.0/15.7.

What is the Stock P/E of Dr Lalchandani Labs Ltd?

The Stock P/E of Dr Lalchandani Labs Ltd is 18.3.

What is the Book Value of Dr Lalchandani Labs Ltd?

The Book Value of Dr Lalchandani Labs Ltd is 22.0.

What is the Dividend Yield of Dr Lalchandani Labs Ltd?

The Dividend Yield of Dr Lalchandani Labs Ltd is 0.00 %.

What is the ROCE of Dr Lalchandani Labs Ltd?

The ROCE of Dr Lalchandani Labs Ltd is 6.53 %.

What is the ROE of Dr Lalchandani Labs Ltd?

The ROE of Dr Lalchandani Labs Ltd is 6.95 %.

What is the Face Value of Dr Lalchandani Labs Ltd?

The Face Value of Dr Lalchandani Labs Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Dr Lalchandani Labs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE